D-FI

Serial Number 97149164
602

Registration Progress

Application Filed
Nov 30, 2021
Under Examination
Jul 11, 2023
Approved for Publication
May 16, 2023
Published for Opposition
May 16, 2023
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: D-FI
Previous Owner: Castle Creek Biosciences, LLC
Classes: 005

Trademark Image

D-FI

Basic Information

Serial Number
97149164
Filing Date
November 30, 2021
Published for Opposition
May 16, 2023
Abandonment Date
May 14, 2025
Drawing Code
4

Status Summary

Current Status
Inactive
Status Code
602
Status Date
May 30, 2025
Classes
005

Rights Holder

Castle Creek Biosciences, LLC

16
Address
405 Eagleview Boulevard
Exton, PA 19341

Ownership History

Castle Creek Biosciences, LLC

Original Applicant
16
Exton, PA

Castle Creek Biosciences, LLC

Owner at Publication
16
Exton, PA

Legal Representation

Attorney
Edward F. Behm, Jr.

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

41 events
Date Code Type Description Documents
May 30, 2025 MAB2 E ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND Loading...
May 30, 2025 ABN2 O ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Loading...
Feb 13, 2025 XELG O APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Loading...
Feb 13, 2025 XELR I APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Loading...
Nov 13, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Nov 13, 2024 GNRT O NON-FINAL ACTION E-MAILED Loading...
Nov 13, 2024 CNRT W SU - NON-FINAL ACTION - WRITTEN Loading...
Oct 29, 2024 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Jan 11, 2024 IUAF S USE AMENDMENT FILED Loading...
Jan 30, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jan 29, 2024 EX1G S SOU EXTENSION 1 GRANTED Loading...
Jan 11, 2024 EXT1 S SOU EXTENSION 1 FILED Loading...
Jan 29, 2024 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Jan 11, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jan 11, 2024 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Jul 11, 2023 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
May 16, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
May 16, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
Apr 26, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Apr 11, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Apr 6, 2023 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Apr 6, 2023 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Apr 6, 2023 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Apr 6, 2023 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Mar 20, 2023 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Mar 20, 2023 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Mar 20, 2023 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Mar 20, 2023 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Mar 15, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Mar 13, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Mar 13, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Sep 13, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Sep 13, 2022 GNRT F NON-FINAL ACTION E-MAILED Loading...
Sep 13, 2022 CNRT R NON-FINAL ACTION WRITTEN Loading...
Sep 8, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 31, 2022 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Aug 31, 2022 EWAF I TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS Loading...
Aug 31, 2022 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Aug 31, 2022 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Dec 4, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Dec 3, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Gene therapy products, namely, genetically modified cells for medical use for the treatment of dystrophic epidermolysis bullosa; pharmaceutical preparations and injectable biological preparations containing genetically modified materials for treatment of dystrophic epidermolysis bullosa; Pharmaceutical preparations and therapeutic preparations for treatment of skin diseases, connective tissue diseases, arthritis and autoimmune diseases
First Use Anywhere: Jan 22, 2022
First Use in Commerce: Jan 22, 2022

Classification

International Classes
005